A new report launched today lays out clear recommendations to boost access to value added medicines in Europe.
The IQVIA report points out the necessary adjustments to healthcare processes from defining regulatory pathways to pricing and reimbursement policies that consider value added benefits based on tailored and efficient use of evidence. The report also flags the importance of multi-stakeholder decision-making and collaboration through best in class examples such as the new pricing and reimbursement system in Belgium.
The report was presented to the European Parliament and stakeholders in Brussels, at an event hosted by Member of the European Parliament (MEP) Lieve Wierinck. Panellists from the patient community, physicians groups, nurse’s representatives, hospital pharmacists, and payers debated the way forward for better access to value added medicines for better health.
The IQVIA report cited the avenues to incentivise the development of patient-centric and continuous innovation. These pragmatic recommendations based on real case studies across Europe show that there are clear options to value continuous innovation so that it can reach patients in need.
Speaking at the launch event, Arun Narayan, Chair of the Value Added Medicines group said “Our healthcare systems must seize the opportunity of improving patient access to continuous innovation. Today, we heard the voice of the healthcare community on the need for value added medicines and the key priorities to improve the current environment. We encourage governments to recognise the need for Value Added Medicines and to benchmark the positive examples cited in the IQVIA report to enhance outcomes for patients.”